Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 1.9% – What’s Next?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s share price rose 1.9% on Wednesday . The stock traded as high as $1.14 and last traded at $1.10. Approximately 53,853 shares were traded during mid-day trading, a decline of 23% from the average daily volume of 70,350 shares. The stock had previously closed at $1.08.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Enlivex Therapeutics in a report on Wednesday, December 11th.

Enlivex Therapeutics Trading Up 1.9 %

The stock has a market cap of $23.55 million, a P/E ratio of -1.12 and a beta of 0.99. The stock has a 50 day simple moving average of $1.18 and a 200 day simple moving average of $1.29.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings results on Friday, November 29th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. Equities analysts anticipate that Enlivex Therapeutics Ltd. will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Enlivex Therapeutics

A hedge fund recently bought a new stake in Enlivex Therapeutics stock. Sigma Investment Counselors Inc. purchased a new position in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 30,000 shares of the company’s stock, valued at approximately $50,000. Sigma Investment Counselors Inc. owned approximately 0.14% of Enlivex Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.